Market Overview:
The global chronic respiratory diseases treatment market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as the increasing prevalence of chronic respiratory diseases, rising awareness about these diseases, and technological advancements in the field of respiratory disease treatment. Based on type, the global chronic respiratory diseases treatment market is segmented into corticosteroids, bronchodilators, monoclonal antibodies, antibiotics, mucolytic agents, leukotriene modifiers and others. Bronchodilators are expected to dominate the market during the forecast period owing to their high usage for treating asthma and COPD. Based on application, retail pharmacies accounted for majority share of the global chronic respiratory diseases treatment market in 2017 and this trend is anticipated to continue during the forecast period as well.
Product Definition:
Chronic respiratory diseases (CRDs) are a group of lung conditions that persist or recur over a long period of time. They include chronic obstructive pulmonary disease (COPD), bronchiectasis, and cystic fibrosis. CRDs are the third leading cause of death in the United States, after heart disease and cancer. Treatment for CRDs is aimed at relieving symptoms and preventing further deterioration of lung function. Treatment may include medications such as bronchodilators and steroids, oxygen therapy, chest physical therapy, and surgery.
Corticosteroids:
Corticosteroids are the group of drugs which act as anti-inflammatory agents. They are used for the treatment of asthma, bronchitis and other respiratory diseases. Corticosteroid is a type of drug that reduces inflammation by inhibiting the production or action of cytokines (substances that cause inflammation). Corticosteroids may be given in combination with antibiotics to reduce infection during treatment.
Bronchodilators:
Bronchodilators are drugs that widen the airways and increase the flow of air in to lung tissue. They work by relaxing smooth muscles in bronchi, which reduces resistance to airflow. Bronchodilators are used for treating conditions such as chronic obstructive pulmonary disease (COPD), asthma, and other breathing disorders.
Application Insights:
The retail pharmacies segment dominated the global chronic respiratory diseases treatment market in 2017. This can be attributed to factors such as rising prevalence of target diseases, increasing awareness about availability of treatments, and growing emphasis on early diagnosis. Moreover, a rise in demand for inhalers due to increased asthma incidence is also expected to drive growth over the forecast period.
Hospital pharmacies are anticipated to witness significant growth owing to an increase in hospitalization rates for various chronic respiratory diseases including asthma and COPD. For instance, according with data published by Global Burden of Disease Study 2016-2017 (GBD), around 1 billion prescriptions were written every year for long-term bronchodilators which were dispensed from hospital pharmacies across Europe and America combined. Thus growing importance of effective management & treatment of target conditions coupled with high prevalence levels are expected fuel segment expansion during the forecast period (2018 - 2030).
Regional Analysis:
North America dominated the global chronic respiratory diseases treatment market in 2017. High adoption of advanced therapeutics for treating COPD and asthma, increasing healthcare expenditure, and high prevalence of target diseases are some major factors responsible for its dominance. Moreover, growing awareness about chronic respiratory diseases treatment options is also expected to drive growth during the forecast period.
Asia Pacific is anticipated to be the fastest-growing region over the forecast period owing to rising disposable income levels and improving healthcare infrastructure in emerging countries such as China & India & Indonesia & Philippines among others. Furthermore, an increase in foreign direct investments by international players seeking high growth opportunities coupled with supportive government initiatives are other factors driving regional market growth during the same period.
Growth Factors:
- Increasing prevalence of chronic respiratory diseases such as asthma, COPD, and bronchitis is expected to drive the growth of the chronic respiratory diseases treatment market.
- Rising awareness about the available treatment options for chronic respiratory diseases is anticipated to fuel the growth of this market in the coming years.
- The increasing number of smokers and elderly population are likely to contribute significantly to the growth of this market in future.
- Technological advancements in diagnosis and treatment procedures are projected to boost the demand for chronic respiratory diseases treatments over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Chronic Respiratory Diseases Treatment Market Research Report
By Type
Corticosteroids, Bronchodilators, Monoclonal Antibodies, Antibiotics, Mucolytic Agents, Leukotriene Modifiers, Others
By Application
Retail Pharmacies, Hospital Pharmacies, Mail Order Pharmacies
By Companies
Mylan, Teva Pharmaceutical, Sumitomo Dainippon Pharma, Merck, Boehringer Ingelheim Pharmaceuticals, AstraZeneca, GlaxoSmithKline, Mylan
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
179
Number of Tables & Figures
126
Customization Available
Yes, the report can be customized as per your need.
Global Chronic Respiratory Diseases Treatment Market Report Segments:
The global Chronic Respiratory Diseases Treatment market is segmented on the basis of:
Types
Corticosteroids, Bronchodilators, Monoclonal Antibodies, Antibiotics, Mucolytic Agents, Leukotriene Modifiers, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Retail Pharmacies, Hospital Pharmacies, Mail Order Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Mylan
- Teva Pharmaceutical
- Sumitomo Dainippon Pharma
- Merck
- Boehringer Ingelheim Pharmaceuticals
- AstraZeneca
- GlaxoSmithKline
- Mylan
Highlights of The Chronic Respiratory Diseases Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Corticosteroids
- Bronchodilators
- Monoclonal Antibodies
- Antibiotics
- Mucolytic Agents
- Leukotriene Modifiers
- Others
- By Application:
- Retail Pharmacies
- Hospital Pharmacies
- Mail Order Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Chronic Respiratory Diseases Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Chronic respiratory diseases treatment is a combination of treatments that are used to manage and treat chronic respiratory diseases. Treatment may include medications, oxygen therapy, ventilation support, and other therapies.
Some of the key players operating in the chronic respiratory diseases treatment market are Mylan, Teva Pharmaceutical, Sumitomo Dainippon Pharma, Merck, Boehringer Ingelheim Pharmaceuticals, AstraZeneca, GlaxoSmithKline, Mylan.
The chronic respiratory diseases treatment market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Chronic Respiratory Diseases Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Chronic Respiratory Diseases Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Chronic Respiratory Diseases Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Chronic Respiratory Diseases Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Chronic Respiratory Diseases Treatment Market Size & Forecast, 2018-2028
4.5.1 Chronic Respiratory Diseases Treatment Market Size and Y-o-Y Growth
4.5.2 Chronic Respiratory Diseases Treatment Market Absolute $ Opportunity
Chapter 5 Global Chronic Respiratory Diseases Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Chronic Respiratory Diseases Treatment Market Size Forecast by Type
5.2.1 Corticosteroids
5.2.2 Bronchodilators
5.2.3 Monoclonal Antibodies
5.2.4 Antibiotics
5.2.5 Mucolytic Agents
5.2.6 Leukotriene Modifiers
5.2.7 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Chronic Respiratory Diseases Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Chronic Respiratory Diseases Treatment Market Size Forecast by Applications
6.2.1 Retail Pharmacies
6.2.2 Hospital Pharmacies
6.2.3 Mail Order Pharmacies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Chronic Respiratory Diseases Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Chronic Respiratory Diseases Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Chronic Respiratory Diseases Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Chronic Respiratory Diseases Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Chronic Respiratory Diseases Treatment Market Size Forecast by Type
9.6.1 Corticosteroids
9.6.2 Bronchodilators
9.6.3 Monoclonal Antibodies
9.6.4 Antibiotics
9.6.5 Mucolytic Agents
9.6.6 Leukotriene Modifiers
9.6.7 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Chronic Respiratory Diseases Treatment Market Size Forecast by Applications
9.10.1 Retail Pharmacies
9.10.2 Hospital Pharmacies
9.10.3 Mail Order Pharmacies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Chronic Respiratory Diseases Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Chronic Respiratory Diseases Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Chronic Respiratory Diseases Treatment Market Size Forecast by Type
10.6.1 Corticosteroids
10.6.2 Bronchodilators
10.6.3 Monoclonal Antibodies
10.6.4 Antibiotics
10.6.5 Mucolytic Agents
10.6.6 Leukotriene Modifiers
10.6.7 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Chronic Respiratory Diseases Treatment Market Size Forecast by Applications
10.10.1 Retail Pharmacies
10.10.2 Hospital Pharmacies
10.10.3 Mail Order Pharmacies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Chronic Respiratory Diseases Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Chronic Respiratory Diseases Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Chronic Respiratory Diseases Treatment Market Size Forecast by Type
11.6.1 Corticosteroids
11.6.2 Bronchodilators
11.6.3 Monoclonal Antibodies
11.6.4 Antibiotics
11.6.5 Mucolytic Agents
11.6.6 Leukotriene Modifiers
11.6.7 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Chronic Respiratory Diseases Treatment Market Size Forecast by Applications
11.10.1 Retail Pharmacies
11.10.2 Hospital Pharmacies
11.10.3 Mail Order Pharmacies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Chronic Respiratory Diseases Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Chronic Respiratory Diseases Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Chronic Respiratory Diseases Treatment Market Size Forecast by Type
12.6.1 Corticosteroids
12.6.2 Bronchodilators
12.6.3 Monoclonal Antibodies
12.6.4 Antibiotics
12.6.5 Mucolytic Agents
12.6.6 Leukotriene Modifiers
12.6.7 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Chronic Respiratory Diseases Treatment Market Size Forecast by Applications
12.10.1 Retail Pharmacies
12.10.2 Hospital Pharmacies
12.10.3 Mail Order Pharmacies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Chronic Respiratory Diseases Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Chronic Respiratory Diseases Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Chronic Respiratory Diseases Treatment Market Size Forecast by Type
13.6.1 Corticosteroids
13.6.2 Bronchodilators
13.6.3 Monoclonal Antibodies
13.6.4 Antibiotics
13.6.5 Mucolytic Agents
13.6.6 Leukotriene Modifiers
13.6.7 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Chronic Respiratory Diseases Treatment Market Size Forecast by Applications
13.10.1 Retail Pharmacies
13.10.2 Hospital Pharmacies
13.10.3 Mail Order Pharmacies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Chronic Respiratory Diseases Treatment Market: Competitive Dashboard
14.2 Global Chronic Respiratory Diseases Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Mylan
14.3.2 Teva Pharmaceutical
14.3.3 Sumitomo Dainippon Pharma
14.3.4 Merck
14.3.5 Boehringer Ingelheim Pharmaceuticals
14.3.6 AstraZeneca
14.3.7 GlaxoSmithKline
14.3.8 Mylan
